P-0230 - Salvage chemotherapy in metastatic colorectal cancer with combination of capecitabine and mitomycin C

Date 28 June 2014
Event World GI 2014
Session Poster Session
Topics Anti-Cancer Agents & Biologic Therapy
Colon Cancer
Rectal Cancer
Presenter Aneta Zygulska
Citation Annals of Oncology (2014) 25 (suppl_2): ii14-ii104. 10.1093/annonc/mdu165
Authors A. Zygulska1, K. Krzemieniecki2
  • 1University Hospital, Krakow/PL
  • 2Oncological Department Collegium Medicum Jagiellonian University, Krakow/PL



A significant proportion of heavily pretreated patients with metastatic colorectal cancer present good performance status (PS) and are eligible for further systemic treatment. Mitomycin C (MMC) and capecitabine can be considered as a salvage treatment in this group of patients as at least third line of the systemic treatment.


Twenty seven patients (16 males and 11 females), median age 56,3 years with metastatic colorectal cancer were treated with capecitabine and MMC as their third or further line systemic treatment in Oncological Department of University Hospital in Cracow, Poland between July 2011 and December 2013. Chemotherapy consisted of intravenous MMC 6 mg/m2 on day 1 and oral capecitabine 1000 mg/m2 twice daily on days 1-14 followed by 7-days rest. Treatment courses were repeated every 3 weeks unless there was evidence of progressive disease or unacceptable toxicity.


All out of 27 patients were evaluable for response and toxicity. A total of 96 cycles were administered. After three cycles of chemotherapy18,5% patients had stable disease and 74,1% patients progressed (14/20 – radiologically confirmed progression – and 6/20 – deterioration of performance status within chemotherapy). One patient (3,7%) died due to cardiac infarct. One patient (3,7%) has been within treatment (before the evaluation). Median overall survival (OS) was 4,7 months. Toxicity was mild and easily manageable. Toxicity (G3) included thrombocytopenia 7,4%, diarrhea 3,7% and fatigue 3,7%.


1. Mitomycin C and capecitabine can be considered as a salvage therapy in heavily pretreated patients with metastatic colorectal cancer and with good performance status. 2. Toxicity of these drugs combination is acceptable and easily manageable.